Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhalation preparation

A technology for inhalation preparations and buffers, which is applied in the field of inhalation preparations and aerosol inhalation preparations for treating diabetes drugs, and can solve problems such as poor stability and reduced tendency of insulin aspart to form hexamers

Pending Publication Date: 2022-05-06
SUNSHINE LAKE PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Insulin aspart has a reduced propensity to form hexamers, making it less stable than human insulin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalation preparation
  • Inhalation preparation
  • Inhalation preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Example 1 investigation of asparagus insulin lyophilized powder: screening of lyophilized protective agent

[0095] Table 1-1: prescription table

[0096]

[0097] Preparation process:

[0098] (1) Add zinc oxide to dilute hydrochloric acid, completely react and dissolve, and then add water to fix the volume;

[0099] (2) Add disodium hydrogen phosphate dihydrate, sodium chloride and freeze-drying protective agent to water, stir and dissolve completely, add pH regulator to adjust pH to 7.2 ~ 7.6 to obtain solution a;

[0100] (3) Add insulin aspartate into water, stir and disperse, adjust the pH to 2.5-3.0, stir and dissolve until clear, add (1) the prepared zinc ion solution, stir evenly, and then adjust the pH to about 7.2-7.6 to obtain solution B;

[0101] (4) Add solution a to solution B under stirring conditions, stir evenly and freeze dry.

[0102] See table 1-2 for freeze-drying parameters and table 1-3 for stability results.

[0103] Table 1-2: freeze drying param...

Embodiment 2

[0108] Example 2 investigation of asparagus insulin lyophilized powder: buffer screening

[0109] Table 2-1: prescription table

[0110]

[0111] Preparation process:

[0112] (1) Add zinc oxide to dilute hydrochloric acid, completely react and dissolve, and then add water to fix the volume;

[0113] (2) Add anhydrous lactose, sodium chloride and buffer into water, stir and dissolve completely, adjust the pH to 7.2 ~ 7.6 to obtain solution a;

[0114] (3) Add insulin aspartate into water, stir and disperse, adjust the pH to 2.5-3.0, stir and dissolve until clear, add (1) the prepared zinc ion solution, stir evenly, and then adjust the pH to about 7.2-7.6 to obtain solution B;

[0115] (4) Add solution a to solution B under stirring conditions, stir evenly and freeze dry.

[0116] See table 2-2 for freeze-drying parameters and table 2-3 for stability results.

[0117] Table 2-2: freeze drying parameters

[0118]

[0119] Table 2-3: stability results of each batch of samples place...

Embodiment 3

[0122] Example 3 investigation of asparagus insulin solution: screening of antimicrobial agents

[0123] Table 3-1: prescription table

[0124]

[0125]

[0126] Preparation process:

[0127] (1) Add zinc oxide to dilute hydrochloric acid, completely react and dissolve, and then add water to fix the volume;

[0128] (2) Add glycerin, disodium hydrogen phosphate dihydrate, sodium chloride and bacteriostatic agent into water, stir and dissolve them completely, and adjust the pH to 7.2 ~ 7.6 to obtain solution a;

[0129] (3) Add insulin aspartate into water, stir and disperse, adjust the pH to 2.5-3.0, stir and dissolve until clear, add (1) the prepared zinc ion solution, stir evenly, and then adjust the pH to about 7.2-7.6 to obtain solution B;

[0130] (4) Add solution a to solution B under stirring conditions, stir evenly, fix the volume, filter and sterilize.

[0131] The stability results of each batch are shown in table 3-2.

[0132] Table 3-2: stability results of each ba...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to an insulin aspart inhalation preparation, and belongs to the technical field of pharmacy. The inhalation preparation is used for treating diabetes; the inhalation preparation comprises a freeze-drying protective agent, a buffering agent, a stabilizing agent, an isoosmotic adjusting agent, a bacteriostatic agent and the like. The inhalation preparation can improve the compliance of a patient, reduce the medication difficulty of the patient and reduce adverse reactions to the throat and the lung; the inhalation preparation is good in stability, the concentration of the medicine in the respiratory tract can be improved, the administration dosage is reduced, and the medication safety is improved.

Description

technical field [0001] The invention relates to an inhalation preparation, in particular to an atomized inhalation preparation for treating diabetes drugs, belonging to the pharmaceutical technical field. Background technology [0002] Insulin is an effective and commonly used drug for the treatment of diabetes. Due to insufficient insulin or relatively insufficient insulin or decreased insulin sensitivity in diabetics, postprandial blood glucose can not be effectively reduced to maintain the fasting level after postprandial blood glucose rise. Therefore, it is necessary to give postprandial insulin to control. At present, the listed dietary insulin preparations include recombinant human insulin, aspart insulin, lispro insulin and glutathione insulin. [0003] Insulin aspart is a fast acting insulin derivative produced by Saccharomyces cerevisiae using recombinant DNA technology. It is a quick acting insulin analog that uses genetic engineering DNA recombination technology to rep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/28A61K9/72A61K9/19A61K9/08A61K47/02A61K47/12A61K47/18A61K47/26A61P3/10
CPCA61K9/0078A61K9/0075A61K9/19A61K9/08A61K38/28A61K47/12A61K47/26A61K47/183A61K47/02A61P3/10
Inventor 胡伟健牟丽秋赵步文游劲松黄芳芳
Owner SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com